NCT03756558已完成不适用
Cross-SealTM IDE Trial: Prospective, Multi-Center, Single Arm Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 147
- 试验地点
- 40
- 主要终点
- Freedom From Major Complications
研究概览
简要总结
This study evaluates the safety and effectiveness of the Cross-Seal vascular closure device in gaining post procedure hemostasis in subjects undergoing interventional procedures requiring an 8 to 18 french size introducer sheath.
详细描述
The Cross-Seal device is a VCD intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (8-18F ID) interventional devices. The function of Cross-Seal is to percutaneously close the puncture in the artery wall (arteriotomy) through which the catheters were inserted for the procedure.
The study is being conducted to demonstrate the safety and effectiveness of Cross-Seal in achieving hemostasis in femoral arterial access sites in subjects undergoing percutaneous transcatheter interventional procedures using a large-bore procedure sheath.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is ≥ 18 years old
- •Subject is scheduled for elective or planned (i.e., not emergent or urgent) percutaneous transcatheter interventional procedures involving access through the femoral artery using 8-18 French introducer sheaths
- •Subject is able to undergo emergent vascular surgery if a complication related to the vascular closure necessitates such surgery
- •Subject is willing and able to complete follow-up requirements
- •Subject, or authorized representative signs a written Informed Consent form prior participating in the study
排除标准
- •General Exclusion Criteria
- •Prior intra-aortic balloon pump at access site
- •Subjects with severe inflow disease (iliac artery diameter stenosis > 50%) and/or severe peripheral arterial disease (Rutherford Classification 5 or 6), as confirmed with prior standard of care Computed Tomography Imaging, duplex ultrasound, and/or intra-procedural fluoroscopy
- •Common femoral artery lumen diameter is < 5 mm
- •In opinion of the investigator, significant scarring of the target access site which would preclude use of the device in accordance with the IFU
- •Prior target artery closure with any closure device < 90 days, or closure with manual compression ≤ 30 days prior to index procedure
- •Prior vascular surgery, vascular graft, or stent in region of access site
- •Subjects receiving glycoprotein IIb/IIIa inhibitors before, during, or after the catheterization procedure
- •Subjects with significant anemia
- •Subject with known bleeding disorder including thrombocytopenia (platelet count < 100,000), thrombasthenia, hemophilia or Von Willebrand's disease
- •Subject with renal insufficiency, on dialysis therapy, or with renal transplant
- •Known severe allergy to contrast reagent that cannot be managed with premedication
- •Inability to tolerate aspirin and/or other anticoagulation/antiplatelet treatment
- •Planned anticoagulation therapy post-procedure such that the Activated Clotting Time (ACT) is expected to be elevated above 350 seconds for more than 24 hours after the procedure
- •Connective tissue disease (e.g., Marfan's Syndrome)
- •Thrombolytics (e.g., streptokinase, urokinase), Angiomax (bivalirudin) or other thrombin-specific anticoagulants ≤ 24 hours prior to the procedure
- •Recent (within 8 weeks) cerebrovascular accident or Q-wave myocardial infarction
- •Subjects who are morbidly obese
- •Planned major intervention or surgery, including planned endovascular procedure in the target leg, within 30 days following the interventional procedure
- •Subject unable to ambulate at baseline (i.e., confined to wheelchair or bed)
- •Currently participating in a clinical study of an investigational device or drug that has not completed its primary study endpoint
- •Known allergy to any device component
- •Subject is known or suspected to be pregnant or lactating
- •Evidence of active systemic or local groin infection
- •Subject has other medical, social or psychological problem that in the opinion of the investigator precludes them from participating
- •Subject is mentally incompetent or a prisoner
- •New York Heart Association (NYHA) Class IV heart failure that is uncontrolled and requires treatment in the Intensive Care Unit within 24 hours prior to the index procedure
- •Left Ventricular Ejection Fraction (LVEF) < 20%
- •Unilateral or bilateral lower extremity amputation
- •Known existing nerve damage in the target leg
- •Subjects who have already participated in this study
- •Intra-Procedure Exclusion Criteria
- •Access site above the most inferior border of the inferior epigastric artery (IEA) and/or above the inguinal ligament based upon bony landmarks
- •Access site in the profunda femoris or superficial femoral arteries, or the bifurcation of these vessels
- •Ipsilateral femoral venous sheath during the catheterization procedure
- •Common femoral artery calcium, which is visible with prior Computed Tomography Imaging and/or duplex ultrasound
- •Subject in which there is difficulty inserting the introducer sheath or need for greater than 2 ipsilateral arterial punctures at the start of the catheterization procedure
- •Difficulty in obtaining vascular access resulting in multiple arterial punctures and/or posterior arterial puncture
- •Evidence of a pre-existing hematoma (> 1.5 cm in diameter), arteriovenous fistula, pseudoaneurysm, or intraluminal thrombosis at the access site
- •Marked tortuosity (at the investigator's discretion) of the femoral or external iliac artery in the target leg based on prior Computed Tomography imaging, fluoroscopy, and/or duplex ultrasound
- •Angiographic evidence of arterial laceration, dissection, or stenosis in the femoral artery that would preclude use of the investigational device
- •Target arteriotomy >18 French sheath
结局指标
主要结局
Freedom From Major Complications
时间窗: 30 days post procedure
Freedom from major complications of the target limb. Major Complications include: access site vascular injury that requires surgical intervention, access related lower extremity ischemia, access site infection
Mean Time To Hemostasis (TTH)
时间窗: Index Procedure
The mean Time To Hemostasis in the Common Femoral Artery (CFA) of the target limb access site with use of the investigational device.
次要结局
- Incidence of Treatment Success(30 days post procedure)
- Incidence of Device Failure(30 days post procedure)
- Incidence of Adverse Events(60 days post procedure)
- Freedom From Minor Complications(30 days post procedure)
- Number of Participants With Device Related Complications Within 30 Days Post-procedure(30 days post procedure)
- Incidence of Adverse Events(60 days post procedure)
- Incidence of Technical Success(Immediately Post-procedure (procedure approximately 8 hours))
- Incidence of Closure Success(Within 48 hours of the index procedure or hospital discharge, whichever occurs first)
- Incidence of Treatment Success(30 days post procedure)
- Incidence of Surgical or Endovascular Intervention Post Closure(30 days post procedure)
- Incidence of Manual Compression(Post-procedure, following use of the investigational device until achieve hemostasis, assessed approximately up to 48 hours)
- Time-to-Ambulation:(From the final procedural sheath removal to time when the subject stands and walks at least 20 feet without re-bleeding, assessed up to approximately 48 hours)
- Incidence of Device Failure(30 days post procedure)
- Incidence of Procedure Related Complications(30 days post procedure)
研究者
研究点 (40)
Loading locations...
相似试验
进行中（未招募）
不适用
PerQseal® Clinical StudyPercutaneous Large Hole Vascular ClosureNCT05653336Vivasure Medical Limited149
终止
不适用
InSeal Vascular Closure Device Clinical Study ProtocolPercutaneous Closure of Artery Access SitesNCT01896401InSeal Medical Ltd.33
已完成
不适用
MANTA Percutaneous Vascular Closure Device - The SAFE MANTA StudyFemoral Arteriotomy ClosureNCT02908880Essential Medical, Inc.263
招募中
不适用
To study safety and efficacy of vascular closure devices used for control of bleeding from skin site in groin region after angioplasty and compare with bleeding control by radial band from skin at forearm site.CTRI/2014/08/004852PGIMER100
终止
不适用
VenaSeal Spectrum: Global Post-Market Randomized Controlled TrialVenous RefluxNCT03820947Medtronic Endovascular506